SCOLR starts studies
This article was originally published in The Tan Sheet
Executive Summary
SCOLR Pharma announces Nov. 1 the start of the first of three trials to evaluate the safety and efficacy of its OTC 12-hour CDT-based ibuprofen. The Bellevue, Wash.-based firm expects to complete the trials of its controlled delivery technology ibuprofen by the end of the first quarter of 2008, and plans to file a new drug application in the second half of 2008...
You may also be interested in...
SCOLR’s sales and earnings
SCOLR Pharma's net revenues in its fiscal 2007 declined 13 percent to $2 million, the Bellevue, Wash.-based firm says in a March 11 release. Royalty income related to SCOLR's alliance with Perrigo increased 38 percent to $1.2 million in 2007, however, the gain was offset by a decrease in research and development revenue associated with the termination of an agreement with Wyeth Consumer Healthcare, the firm notes. SCOLR's net loss for the year was $10.6 million compared to $10.7 million in 2006. Achievements in 2007 include the completion of two of three product performance trials to evaluate the safety and efficacy of OTC 12-hour ibuprofen with controlled delivery technology (1"The Tan Sheet" Nov. 5, 2007, In Brief). The third trial is slated for completion by the end of the second quarter this year, and the firm plans to submit its new drug application for the product in the second half of the year...
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.